Clinical Trials Logo

Duodenal Neoplasms clinical trials

View clinical trials related to Duodenal Neoplasms.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06411795 Recruiting - Pancreatic Neoplasm Clinical Trials

Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy

Start date: November 10, 2023
Phase: Phase 2
Study type: Interventional

This phase II trial compares the effect of rectus sheath block with liposomal bupivacaine to thoracic epidural analgesia (TEA) on pain control in patients following surgical removal of all or part of the pancreas and duodenectomy (pancreatoduodenectomy). Administering long acting local anesthetics, such as liposomal bupivacaine, in between the muscle layers of the abdomen (rectus sheath block) may help with pain relief during and after surgery. TEA uses a needle to insert a flexible plastic catheter into the thoracic spine to administer anesthetic and pain medication, such as bupivacaine and hydromorphone, to treat pain in the thoracic and upper abdominal areas during and after surgery. Epidurals have been successfully used to treat pain after surgery, however, it does have a risk of low blood pressure which may limit the use in the thoracic approach. Rectus sheath blocks with liposomal bupivacaine may be as effective as TEA in reducing pain in patients following a pancreatoduodenectomy.

NCT ID: NCT06033976 Recruiting - Clinical trials for Neoplasm, Colorectal

Endoscopic Submucosal Dissection Registry

ESDREG
Start date: January 1, 2021
Phase:
Study type: Observational [Patient Registry]

This is a patient registry for all cases of pre-neoplastic or early neoplastic digestive tract lesions treated with curative intention by endoscopic submucosal dissection (ESD) technique.

NCT ID: NCT05688020 Recruiting - Clinical trials for Esophageal Neoplasms

Tranexamic Acid During Upper GI Endoscopic Resection Procedures

Start date: February 1, 2023
Phase: Phase 4
Study type: Interventional

Endoscopic resection of gastrointestinal lesions may prevent cancer. However, resection is associated with adverse events such as bleeding. Tranexamic acid (TXA) is a synthetic derivative of lysine that exerts antifibrinolytic effects and may prevent bleeding. The investigators aim to evaluate the effect of local TXA on preventing intraprocedural and postprocedural bleeding in patients undergoing endoscopic mucosal resection (EMR) of upper gastrointestinal lesions.

NCT ID: NCT05428553 Recruiting - Duodenal Tumor Clinical Trials

CSP vs EMR for >6mm Superficial Non-ampullary Duodenal Tumors

CSP; EMR
Start date: June 1, 2022
Phase: N/A
Study type: Interventional

There is currently no reliable evidence on the safety of CSP (cold snare polypectomy) / p-CSP (piecemeal CSP) for SNADT greater than 6mm.In this prospective historical controlled study, we intend to test the role of CSP / p-CSP in the treatment of pedicle less snadt greater than 6mm compared with EMR (endoscopic mucosal resection) / EPMR (endoscopic piecemeal mucosal resection).

NCT ID: NCT04780256 Recruiting - Clinical trials for Esophageal Neoplasms

Endoscopic Resection of Gastrointestinal Neoplasms

Start date: March 15, 2021
Phase:
Study type: Observational

The study aims to retrospectively investigate the endoscopic resection procedures of cancerous and precancerous lesions of the upper and lower digestive tract in order to evaluate the efficacy and safety outcomes and to compare different resection techniques. In particular, the resection techniques investigated will be mucosectomy, en bloc and piecemeal, endoscopic submucosal dissection (ESD) and its variants, full-thickness resection. The anatomical districts involved will be the esophagus, stomach, duodenum, colon and rectum.

NCT ID: NCT04622098 Recruiting - Clinical trials for Esophageal Neoplasms

Prevalence of Sub-epithelial Lesions Among Patients Undergoing EGDs in Egypt

Start date: November 18, 2020
Phase:
Study type: Observational

Subepithelial lesions (SEL) are incidentally observed in the stomach of about 0.3% of middle-aged men and women; half of these are neoplastic. The incidence of subepithelial tumors (SET) of gastrointestinal (GI) origin has risen twofold to fivefold within the past 30 years.The etiology of most SMTs cannot easily be determined by endoscopy. So, we aim to estimate the prevalence and types of sub-epithelial lesions among patients undergoing EGDs in Egypt.

NCT ID: NCT04104230 Recruiting - Pancreatic Cancer Clinical Trials

Quebec Pancreas Cancer Study

QPCS
Start date: March 12, 2012
Phase:
Study type: Observational [Patient Registry]

The Quebec Pancreas Cancer Study is a prospective clinic-based study consisting of clinical, family history and epidemiologic data, with accompanying biospecimens, from patients diagnosed with either pancreas cancer, a related cancer or a related pre-cancerous condition, and their families.

NCT ID: NCT03792048 Recruiting - Cholangiocarcinoma Clinical Trials

Magnetic Compressive Anastomosis for Biliojejunostomy and Pancreaticojejunostomy During Whipple's Procedure

Start date: February 1, 2019
Phase: N/A
Study type: Interventional

Magnetic anastomosis has been attempted in biliary and intestinal reconstruction. Based on our initial experience, the investigators have successfully utilized magnetic anastomosis for biliojejunostomy and pancreaticojejunostomy during pancreaticoduodenectomy. The current study was to design a prospective and case-control study with utilization of magnetic compression anastomosis for pancreaticojejunostomy and biliojejunostomy in Whipple's procedure versus traditional hand-sewn technique on the postoperative morbidity, such as biliary/pancreatic fistula, hemorrhage, anastomotic stenosis, etc. In addition, the investigators are seeking to assess the safety and formation of the anastomosis by magnetic technique.

NCT ID: NCT03189992 Recruiting - Clinical trials for Malignant Tumor of Small Intestine Metastatic to Liver

Study of TCM Syndrome of Hepatocellular Carcinoma and Colorectal Cancer Based on System Science

Start date: January 2014
Phase: Phase 1
Study type: Interventional

Traditional Chinese medicine (TCM) syndrome is a core foundation of disease knowledge, clinical diagnosis and treatment and curative effect evaluation in TCM. "Same TCM Syndrome for Different Diseases" and "Same Treatment for Different Diseases" is one of the characteristics of TCM syndrome differentiation and treatment. This study is the "TCM disease syndrome combination" research baced on principles and methods of system biology, which is through acquisition of primary hepatocellular carcinoma (HCC) and colorectal cancer patients with TCM syndrome information, detection of clinical indicators and genomic, proteomic, and metabolites changes, analyzing the correlation between TCM syndromes and biological information, and revealing its biological material characteristics and the molecular mechanisms of "Same TCM Syndrome for Different Diseases";Developing and implementing the program of TCM syndrome differentiation and treatment for HCC and colorectal cancer to evaluate the efficacy of TCM syndrome based-treatment of HCC and colorectal cancer with TCM syndrom scores, clinical and systems biological indicators, quality of life and survival rate, and to revealing the mechanism of the "Same Treatment for Different Diseases".

NCT ID: NCT03139487 Recruiting - Pancreatic Cancer Clinical Trials

A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism

PRIORITY
Start date: August 7, 2017
Phase: Phase 2
Study type: Interventional

This is an open label, multi-center, and randomized phase II trial designed to compare the safety and efficacy of direct oral anticoagulants and subcutaneous dalteparin in patients with acute venous thromboembolism and upper gastrointestinal, hepatobiliary, or pancreatic cancer, based on a group sequential design. Enrolled patients will be randomized in a 1:1 ratio. Patients will be stratified by performance status, type of cancer, chemotherapy and medical centers.